The Disease Susceptibility Genetic Test-Cancer Screening Package (29 Items)

This test is based on biochip technology to evaluate the risk of 29 high-incidence cancers from the perspective of genetics, and provide guidance to disease prevention.

Test Content of the Disease Susceptibility Genetic Test- (29 Items)

Glioma, meningioma, nasopharyngeal cancer, oral cancer, laryngeal cancer, lung cancer, thyroid cancer, esophageal cancer, stomach cancer, colorectal cancer, liver cancer, pancreatic cancer, gallbladder cancer, cholangiocarcinoma, osteosarcoma, multiple myeloma, skin cancer, bladder cancer, kidney cancer, prostate cancer, testicular germ cell cancer, breast cancer, cervical cancer, endometrial cancer, ovarian cancer, acute lymphoblastic leukemia, acute myeloid leukemia, chronic myelogenous leukemia, non-Hodgkin's lymphoma.

Specification of the Disease Susceptibility Genetic Test-Cancer Screening Package (29 Items)

Sample types

Venous blood

TAT

12 working days

. is the industrialized platform of CapitalBio Corporation and Biochip Beijing National Engineering Research Center and one of the core enterprises of Tsinghua University in the field of life and health. CapitalBio Technology was registered and established in August 2012 and had production, R&D bases and marketing operation centers for biochips, instrument and equipment in Beijing, Shanghai, Chongqing, Chengdu, Dongguan, Hong Kong (China) and San Diego and other places, with a total office area of over 150,000 ㎡ and employees of over 2,000 persons.

As one of , we will do our best to meet all the needs of clients.